Supernus Pharmaceuticals, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $219.06Mn |
Net Profits | $-58.37Mn |
Net Profit Margins | -26.65% |
Supernus Pharmaceuticals, Inc. Common Stock’s revenue jumped 32.4% since last year same period to $219.06Mn in the Q2 2026. On a quarterly growth basis, Supernus Pharmaceuticals, Inc. Common Stock has generated 5.47% jump in its revenue since last 3-months.
Supernus Pharmaceuticals, Inc. Common Stock’s net profit fell -359.44% since last year same period to $-58.37Mn in the Q2 2026. On a quarterly growth basis, Supernus Pharmaceuticals, Inc. Common Stock has generated -2445.62% fall in its net profits since last 3-months.
Supernus Pharmaceuticals, Inc. Common Stock’s net profit margin fell -295.95% since last year same period to -26.65% in the Q2 2026. On a quarterly growth basis, Supernus Pharmaceuticals, Inc. Common Stock has generated -2313.69% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | 0.3 |
EPS Estimate Current Year | 0.3 |
Supernus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a 7.14% jump from last quarter’s estimates.
Supernus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.3.
Key Ratios
Earning Per Share (EPS) | 0.39 |
Supernus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -57.14% since last year same period to 0.39 in the Q2 2026. This indicates that the Supernus Pharmaceuticals, Inc. Common Stock has generated -57.14% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-03 | 0.3 | 0.39 | 30% |
2026-05-05 | 0.28 | 0.21 | -25% |
